15.27 -0.69 (-4.31%)
DNDN
| Trade DNDN now with |
|
Stock Details
Last Trade:15.27 Change:-0.69 (-4.31%) Prev Close:15.96 Open: 16.00 Days Range:15.12 – 16.28 52 Week Range: 6.46 - 43.96 Volume:13017486 P/E: N/AEPS:-3.20
View AllRecent Alerts 02/09/12
Recent Alert on 02/07/12 at 8:28am
Canaccord Genuity Raises Numbers on Dendreon (DNDN); Provenge Outlook Improved on Low Likelihood of New XGEVA Approval
Canaccord Genuity Raises Numbers on Dendreon (DNDN); Provenge Outlook Improved on Low Likelihood of New XGEVA Approval
Canaccord Genuity maintains a 'Buy' on Dendreon (NASDAQ: DNDN) price target raiesd from $16 to $18. Analyst, George Farmer, said, "We maintain our rating and raise our target as a negative FDA stance on Amgen’s (Nasdaq: AMGN) XGEVA de-risks the... Read More
Recent Alert on 02/07/12 at 8:28am
Canaccord Genuity Raises Numbers on Dendreon (DNDN); Provenge Outlook Improved on Low Likelihood of New XGEVA Approval
Canaccord Genuity Raises Numbers on Dendreon (DNDN); Provenge Outlook Improved on Low Likelihood of New XGEVA Approval
Recent Alert on 02/07/12 at 8:28am
Canaccord Genuity Raises Numbers on Dendreon (DNDN); Provenge Outlook Improved on Low Likelihood of New XGEVA Approval
Canaccord Genuity Raises Numbers on Dendreon (DNDN); Provenge Outlook Improved on Low Likelihood of New XGEVA Approval
Recent Alert on 02/07/12 at 8:28am
Canaccord Genuity Raises Numbers on Dendreon (DNDN); Provenge Outlook Improved on Low Likelihood of New XGEVA Approval
Canaccord Genuity Raises Numbers on Dendreon (DNDN); Provenge Outlook Improved on Low Likelihood of New XGEVA Approval
View AllRecent Press Releases
Press Release on 02/07/12 at 9:00am
Perception, Opportunity in Volatility - Research & Analysis on Dendreon Corporation and BioSante Pharmaceuticals, Inc.
Perception, Opportunity in Volatility - Research & Analysis on Dendreon Corporation and BioSante Pharmaceuticals, Inc.
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 02/07/12 at 2:36am
Top Q4 Buys And Sells Of Healthcare-Focused Hambrecht And Quist Capital Management
Top Q4 Buys And Sells Of Healthcare-Focused Hambrecht And Quist Capital Management